ClinicalTrials.gg

TargetBeta

VEGFA

vascular endothelial growth factor A · also VEGF-A, VPF, VEGF · VEGF family

23 programs in company-led studies act on VEGFA, from 21 companies: 8 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (17 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
BevacizumabruleHoffmann-La Rochephase 425048 running–NCIt
RanibizumabruleNovartisphase 41086 running–NCIt
afliberceptruleRegeneron Pharmaceuticalsphase 4895 runningPGFChEMBL
faricimabruleHoffmann-La Rochephase 4172 runningANGPT2NCIt
ivonescimabruleAkesophase 34839 runningPDCD1NCIt
pumitamigBioNTechphase 33432 runningCD274a judged reading
tivunatamigPfizerphase 31515 runningPDCD1the company's pipeline
ABBV-1480RemeGenphase 322 runningPDCD1the company's pipeline
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 322 runningPDCD1NCIt
HLX37Fosun Pharmaphase 322 runningCD274the company's pipeline
surabgene lomparvovecAbbViephase 322 running–the company's pipeline
suvemcitugruleSimcere Pharmaceutical Groupphase 361 running–NCIt
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 244 runningPDCD1a judged reading
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 244 runningPDCD1NCIt
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 233 runningPDCD1NCIt
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010ruleHC Biopharmaphase 222 runningCTLA4, PDCD1NCIt
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207ruleWigen Biomedicine Technology (Shanghai)phase 222 runningPDCD1NCIt
Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18ruleSuzhou Zelgen Biopharmaceuticalsphase 222 runningTGFB1NCIt
Anti-VEGF Antibody-drug Conjugate YL242ruleMediLink Therapeutics (Suzhou)phase 211 running–NCIt
CS2009ruleCStone Pharmaceuticalsphase 211 runningCTLA4the studies' text
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruleTavotek Biotherapeuticsphase 122 runningEGFR, METNCIt
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726ruleCompass Therapeuticsphase 111 runningPDCD1NCIt
SIM0689ruleSimcere Pharmaceutical Groupphase 111 running–the studies' text

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.